Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
36 results about "Aging-associated diseases" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Conditions that develop with increasing age.
Pharmaceutical composition for treating aging-associated diseases, containing progerin expression inhibitor as active ingredient, and screening method of said progerin expression inhibitor
ActiveUS9249153B2Inhibit overexpressionPrevent and treat diseaseCompound screeningOrganic chemistryAge related diseaseAging-associated diseases
Disclosed are a method for treating an aging-related disease and a method for screening a therapeutic agent for an aging-related disease. The method for treating an aging-related disease includes administering to a subject a progerin expression inhibitor as an active ingredient. The method for screening a therapeutic agent for an aging-related disease includes selecting a candidate drug inhibitory of progerin expression.
Owner:PUSAN NAT UNIV IND UNIV COOPERATION FOUND +1
Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
ActiveUS20200009100A1Action potentialSuitable protectionOrganic active ingredientsPowder deliveryDERMATOLOGY/SKINAging-associated diseases
Provided are compounds, pharmaceutical compositions, cosmetic and dermatological compositions or nutritional supplement compositions, comprising omega-3 very-long-chain polyunsaturated fatty acids (n-3 VLC-PUFAs) and / or their endogenous hydroxylated derivatives thereof, known as elovanoids. This disclosure provides methods for neuroprotection, organ and tissue protection or restoration, prevention or slowing down of aging-related diseases and conditions, and sustainment of function during the aging process.
Owner:BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV & AGRI & MECHANICAL COLLEGE +1
Novel chalcone compound and application thereof
PendingCN107973708AImprove fatigue resistanceImprove spontaneous activityOrganic chemistryAntinoxious agentsAge related diseaseOxidation resistant
The invention provides a novel 2-propene-1-one substituted chalcone compound with an anti-aging effect. The novel chalcone compound can serve as a bulk drug for preparing related drugs with anti-oxidation and anti-aging functions of various dosage forms, and has the medical application of treating aging-related diseases.
Owner:王艳艳
Pharmaceutical composition for treating aging-associated diseases, containing progerin expression inhibitor as active ingredient, and screening method of said progerin expression inhibitor
ActiveUS20140039010A1Inhibit overexpressionPrevent and treat diseaseCompound screeningBiocideAge related diseaseAging-associated diseases
Disclosed are a method for treating an aging-related disease and a method for screening a therapeutic agent for an aging-related disease. The method for treating an aging-related disease includes administering to a subject a progerin expression inhibitor as an active ingredient. The method for screening a therapeutic agent for an aging-related disease includes selecting a candidate drug inhibitory of progerin expression.
Owner:PUSAN NAT UNIV IND UNIV COOPERATION FOUND +1
Polysubstituted benzofurans and medicinal applications thereof
The present invention refers to compounds of formula (I):as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and / or chemoprevention of cancer, aging related diseases or processes, diabetes and neurodegenerative diseases.
Owner:UNIV DEL PAIS VASCO +1
Role of p62 in aging-related disease
The application discloses a role of p62 in aging-related disease, such as development of obesity, type 2 diabetes mellitus, non-alcoholic fatty liver, various tumors, increased male mortality, intracellular inclusion named sequestosome, and redox regulation. In particular the application discloses a method of detecting the formation of inclusion bodies in neurodegenerative diseases. The invention further relates to a method of screening for therapeutic agents that disperse the inclusions. Further, transgenic mice containing a mutation in the p62 gene and having a functionally disrupted p62 gene locus are also disclosed.
Owner:SHIN JAEKYOON +1
Thiazoliums and their use for treating protein aging associated diseases
Owner:BEIJING MOLECULE SCI & TECH
Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase
ActiveUS20190350917A1Reduce the amount of solutionReduce proliferationNervous disorderAntibody medical ingredientsLeukotriene-A4 hydrolaseAging-associated diseases
Methods and compositions for treating and / or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and / or preventing aging-related conditions such as neurocognitive disorders.
Owner:ALKAHEST INC
Application of mPGES-2 as drug target for preventing and/or treating aging diseases
ActiveCN114107272AImprove exercise effectProlong survival timeAntinoxious agentsOxidoreductasesAging-associated diseasesPharmaceutical drug
The invention discloses an application of mPGES-2 as a drug target for preventing and / or treating aging diseases. The invention proposes that mPGES-2 is a doxorubicin and hydrogen peroxide induced senescence drug target for the first time. Experiments show that mPGES-2 knockout can significantly prolong the life of adriamycin-induced senescent mice and significantly enhance the athletic ability of the adriamycin-induced senescent mice. Meanwhile, mPGES-2 knockout can obviously inhibit senescence, caused by hydrogen peroxide, of primary mouse fibroblast MEF, and proliferation is promoted. The results show that the doxorubicin-induced senescence phenotype can be improved and the natural senescence of MEF and the accelerated senescence caused by hydrogen peroxide can be delayed by knocking out the mPGES-2, so that the mPGES-2 can be used as a target for preventing and / or treating doxorubicin and / or hydrogen peroxide-induced senescence and senescence-related diseases thereof; and the compound has very important significance on drug development and prevention and / or treatment of the diseases in the future.
Owner:XUZHOU MEDICAL UNIV
A pharmaceutical composition with anti-aging effect
ActiveCN104523733BExtend your lifeHas anti-aging effectsOrganic active ingredientsNervous disorderAging-associated diseasesPterocarpan
Owner:TONGJI UNIV
Thiazoliums and Their Use for Treating Protein Aging Associated Diseases
InactiveUS20110178141A1Promote hardeningHigh sensitivityCosmetic preparationsOrganic active ingredientsThiazoleAging-associated diseases
Owner:BEIJING MOLECULE SCI & TECH
Application of ginseng and polygonum multiflorum compound polysaccharide in preparation of health foods with anti-aging effect
InactiveCN104171797AEnhance antioxidant enzyme activityAnti agingOrganic active ingredientsCosmetic preparationsCell AggregationsDisease
The invention discloses an application of a ginseng and polygonum multiflorum compound polysaccharide in preparation of health foods with an anti-aging effect. The compound polysaccharide is the ginseng and polygonum multiflorum compound polysaccharide which is prepared from ginseng and / or polygonum multiflorum by the processes of water extraction, concentration and alcohol precipitation. The compound polysaccharide disclosed by the invention is capable of effectively prolonging the average life of wild and oxidative stress models and protein aggregation toxic models through the verification of a caenorhabditis elegans model experiment, and the action way thereof is closely related to improvement of nematode antioxidant capacity, inhibition to toxic protein stress, enhancement of heat shock protein activity and adjustment of insulin signal pathway key nodes, thus indicating that the compound polysaccharide has good functions of delaying aging and preventing and treating the diseases related to aging.
Owner:INFINITUS (CHINA) CO LTD
Anti-aging and anti-inflammatory prodrugs and methods of use thereof
PendingCN114341148AOrganic active ingredientsSugar derivativesCarboxyl radicalAging-associated diseases
Provided are anti-aging and anti-inflammatory prodrugs designed from cytotoxic agents incorporated into sites that can be cleaved by SA-beta-gal after delivery of the prodrug in vivo by chemically modifying the cytotoxic agents to release the active parent drug. The prodrugs include a galactosyl moiety, a benzyloxycarboxyl moiety, and a cytotoxic agent moiety, which are preferably acetylated. An anti-aging prodrug for selectively killing one or more senescent cells and / or reducing acute or chronic inflammatory responses in a subject in need thereof is administered to the subject in a therapeutically effective amount of the anti-aging prodrug. The disclosed compositions are useful for reducing one or more symptoms associated with an aging-related disease or disorder or an inflammatory disorder, such as virus-mediated inflammation, in a subject.
Owner:PEKING UNIV
ROLE OF p62 IN AGING-RELATED DISEASE
InactiveUS20080132460A1Nervous disorderGenetic material ingredientsAbnormal tissue growthInclusion bodies
The application discloses a role of p62 in aging-related disease, such as development of obesity, type 2 diabetes mellitus, non-alcoholic fatty liver, various tumors, increased male mortality, intracellular inclusion named sequestosome, and redox regulation. In particular the application discloses a method of detecting the formation of inclusion bodies in neurodegenerative diseases. The invention further relates to a method of screening for therapeutic agents that disperse the inclusions. Further, transgenic mice containing a mutation in the p62 gene and having a functionally disrupted p62 gene locus are also disclosed.
Owner:SHIN JAEKYOON +2
Application of tangerine seed extract in medicine for treating healthy aging
PendingCN114848719AExtend your lifeGood treatment effectAntinoxious agentsPlant ingredientsBiotechnologyAging-associated diseases
The invention relates to the field of medicinal chemistry, in particular to application of a tangerine seed extract in a medicine for treating healthy aging, and the tangerine seed extract is a tangerine seed ethanol extract. It is reported that the tangerine seed extract serves as a potential candidate drug for promoting longevity, the tangerine seed extract prolongs the life of caenorhabditis elegans by activating the autophagy effect, health is promoted, and the tangerine seed extract has a quite large treatment effect on senescence and senescence-related diseases; the clinical application of the tangerine seed extract in senescence and senescence-related diseases can be better promoted.
Owner:SOUTHWEST MEDICAL UNIVERISTY
Mitochondria-targeting compound and composition comprising same for treating or preventing aging-related diseases
PendingUS20220153783A1Effective preventionEffective treatmentOrganic active ingredientsSenses disorderAging-associated diseasesApoptosis
Provided are a mitochondria-targeting compound and a composition including the same for the treatment or prevention of an aging-related disease. A compound according to an aspect or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same are effectively used to prevent or treat aging-related diseases by specifically inducing apoptosis of senescent cells.
Owner:FUSION BIOTECHNOLOGY CO LTD
Polysubstituted benzofurans and medicinal applications thereof
The present invention refers to compounds of formula (I):as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and / or chemoprevention of cancer, aging related diseases or processes, diabetes and neurodegenerative diseases.
Owner:UNIV DEL PAIS VASCO EUSKAL HERRIKO UNIBERTSITATEA +1
Application of Baz2b gene as target spot in senescence alleviation
ActiveCN111500694AReduce expressionReduced activityOrganic active ingredientsCompound screeningAging-associated diseasesPharmaceutical drug
The invention relates to an application of a Baz2b gene as a target spot in senescence alleviation and discloses that the Baz2b gene plays an important role in regulating and controlling the occurrence and development of normal senescence and senescence-related diseases, and the down-adjustment of the Baz2b gene can obviously relieve senescence and improve memory degeneration, behavioral ability degeneration and the like in the senescence process. Therefore, the Baz2b can be used as a research target of senescence and senescence-related diseases, can be used for developing medicines for inhibiting or delaying senescence, and can be used as a marker for diagnosis and prognosis evaluation of senescence and senescence-related diseases.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI
Use of mpges-2 as a target in the development or screening or preparation of drugs for the prevention and/or treatment of diseases of aging
ActiveCN114107272BImprove exercise effectProlong survival timeAntinoxious agentsOxidoreductasesAging-associated diseasesPharmaceutical drug
The invention discloses the application of mPGES‑2 as a drug target for preventing and / or treating aging diseases. The present invention proposes for the first time that mPGES‑2 is a drug target for doxorubicin and hydrogen peroxide-induced senescence. Experiments have shown that mPGES‑2 knockout can significantly prolong the lifespan of doxorubicin-induced aging mice and significantly enhance the exercise capacity of doxorubicin-induced aging mice. At the same time, knockout of mPGES‑2 can significantly inhibit hydrogen peroxide-induced aging of primary mouse fibroblast MEFs and promote proliferation. These results indicate that knocking out mPGES‑2 can improve the senescence phenotype induced by doxorubicin, delay the natural aging of MEFs and the accelerated aging induced by hydrogen peroxide, and indicate that mPGES‑2 can be used as a preventive and / or therapeutic agent for doxorubicin and / or The targets of hydrogen peroxide-induced aging and aging-related diseases are of great significance for the development of drugs and the prevention and / or treatment of such diseases in the future.
Owner:XUZHOU MEDICAL UNIV
Sirt1-T177 site phosphorylation as a biomarker in aging-related diseases
ActiveCN108107198BAnti agingGenetic material ingredientsBiological testingAging-associated diseasesPhosphorylation
The invention belongs to the technical field of molecular diagnostic medicine, and aims to solve the technical problem that a proper target spot and an intervention strategy cannot be provided under the situation that SIRT1 is used for evaluating molecular diagnosis of individual aging and aging-related diseases and delaying individual aging in the prior art. The invention provides application ofSIRT1-T177 locus phosphorylation as a biomarker to aging-related diseases. The SIRT1-T177 locus phosphorylation can be taken as a molecular marker for aging and related diseases, and can be taken as an intervention measure for delaying aging and related diseases; a novel target spot and a novel intervention strategy are provided for the molecular diagnosis of individual aging and aging-related diseases and delaying of individual aging are provided.
Owner:SICHUAN UNIV
Ageing resisting purpose of verapamil
PendingCN111214465ASafe and effective anti-agingCosmetic preparationsToilet preparationsPneumonocyteVerapamil
The invention provides an ageing resisting purpose of verapamil, and specifically provides a purpose of the verapamil, or an optical isomer thereof, or pharmaceutically acceptable salt thereof to preparation of ageing resisting compositions or preparations. The experiment indicates that the verapamil can significantly prolong the life of threadworms; the threadworm health parameter evaluation experiment confirms that the verapamil can improve the movement behavior capacity, the body swinging capacity and the osmotic pressure stress capacity of the threadworms, and reduce vulva integrity defects; and ageing cell dyeing experiment indicates that the verapamil can reduce the ageing rate of human embryonic lung cells. Therefore, the verapamil can be applied to respects of prolonging life, delaying ageing, improving health physiological parameters, reducing the incidence rate of ageing related diseases and the like. The invention also provides products of ageing resisting medicines, health-care products, cosmetics and the like.
Owner:EAST CHINA UNIV OF SCI & TECH
Medicinal use of e3 ligase fbw7 in delaying aging and related diseases
ActiveCN108187035BPrevent agingNervous disorderPeptide/protein ingredientsGenes mutationAging-associated diseases
Disclosed is a use of E3 ligase FBW7 in preparing a drug for delaying aging and for preventing and treating aging-related diseases by means of inhibiting telomere damage, wherein the amino acid sequence of the FBW7 is as shown in SEQ. No.2. Knockout or RNA interference inhibiting the gene expression of the FBW7, a gene mutant expressing the FBW7 competitively inhibiting the FBW7 protein, or the overexpression of TPP1 overcoming the degradation caused by the FBW7 can protect the chromosome telomere from damage caused by stress, such as radiation, bleomycin and hydrogen peroxide, prevent the degradation of TPP1 in the basic state or in the stress state, result in the effect of extending telomere length, increase the number of tissue stem cells, improve the pulmonary respiratory function in the basic state, and prevent the occurrence of lung tissue aging and pulmonary fibrosis in the stress state, and same can be used in preparing a drug for preventing and treating telomere dysfunction to provide ideas and means for anti-aging.
Owner:HANGZHOU NORMAL UNIVERSITY
A kind of construct and its application in preparation of animal senescent cell tracing and senescent cell clearing medicine
ActiveCN112280800BAnimals/human peptidesVector-based foreign material introductionAging-associated diseasesApoptosis
The invention belongs to the field of biotechnology, and discloses a construct integrating the functions of senescent cell localization, tracing, sorting, inducing senescent cell apoptosis and / or clearing senescent cells, and cells or animals transformed by the construct Model. The construct functions by targeting the P21 gene in the genome and inserting it into its proper position. The cells or animal models obtained by the method of the present invention can be used to study aging and aging-related diseases.
Owner:SHANGHAI EAST HOSPITAL EAST HOSPITAL TONGJI UNIV SCHOOL OF MEDICINE
Medicinal uses of the ubiquitin protease usp7 in aging and related diseases
ActiveCN108144050BAvoid degradationPrevents telomere damageNervous disorderPeptide/protein ingredientsAging-associated diseasesTumor cells
Owner:HANGZHOU NORMAL UNIVERSITY
Mutant based on key protein ATG7 of autophagy and application thereof
ActiveCN112390873AOriginal and innovativeEasy to preparePeptide/protein ingredientsAntinoxious agentsPharmacologic actionArginine
The invention belongs to the field of biotechnology and anti-aging treatment, relates to a mutant based on a key protein ATG7 of autophagy and an application thereof in anti-aging treatment, and particularly relates to simulation of a protein modification state through mutation at amino acid sites and an application of the mutant in anti-aging treatment. The mutant based on the key protein ATG7 ofautophagy has an amino acid sequence as shown in SEQ ID No 1, in which the lysines at positions 411 and 413 are mutated into glutamines, and amino acids at positions 513, 514 and 516 are mutated intoarginines. The mutant based on the the key protein ATG7 of autophagy is applied to preparation of drugs for targeting senescence delaying or preventing and treating senescence related diseases. Experiments prove that the mutant based on the the key protein ATG7 of autophagycan play a pharmacological role in delaying senescence by improving the functions of cell nuclei, improving the proliferationstate of cells and improving the metabolic state of cells.
Owner:中国医科大学
A mutant based on autophagy key protein atg7 and its application
ActiveCN112390873BOriginal and innovativeEasy to preparePeptide/protein ingredientsAntinoxious agentsArginineAging-associated diseases
The invention belongs to the field of biotechnology and anti-aging treatment, and relates to a mutant based on the key autophagy protein ATG7 and its application in anti-aging treatment, in particular to simulating protein modification state through amino acid site mutation and its role in anti-aging application in therapy. A mutant based on the key autophagy protein ATG7, its amino acid sequence is SEQ ID No1, wherein the 411th and 413th lysines are mutated to glutamine, and the 513th, 514th and 516th amino acids are mutated to arginine, so The application of the above-mentioned mutant based on the key autophagy protein ATG7 in the preparation of drugs targeted at delaying aging or preventing and treating aging-related diseases. The mutants based on the key autophagy protein ATG7 provided by the present invention have been verified by experiments, and can improve the function of the nucleus, improve the state of cell proliferation, and improve the state of cell metabolism to exert the pharmacological effect of delaying aging.
Owner:中国医科大学
SAB as a biomarker for degenerative diseases and therapeutic sensitivity in cancers
ActiveUS10078090B2Low efficiencyCompound screeningApoptosis detectionDiabetes mellitusAge related disease
The current invention pertains to a method of diagnosing a disease or identifying an increased likelihood of developing the disease in a subject. The method comprises determining the level of Src homology 3 domain binding protein 5 (SH3BP5 or SAB) or the RNA encoding SAB protein in a biological sample obtained from the subject and identifying the subject as having the disease or having an increased likelihood of developing the disease if the biological sample obtained from the subject has an altered level of SAB protein or the RNA encoding SAB protein relative to a control sample. The methods of the current invention can be practiced to diagnose and treat a systemic degenerative disease, a neurodegenerative disease, obesity, diabetes, a cancer, or an aging related disease. The invention also provides a kit for diagnosing a disease or diagnosing an increased likelihood of developing the disease in a subject.
Owner:FLORIDA INTERNATIONAL UNIVERSITY
Composition for preventing or treating cellular senescence-related diseases comprising salinomycin as effective component
PendingUS20220008377A1Recovery functionPrevent obesitySenses disorderAntinoxious agentsVascular endotheliumAging-associated diseases
The present invention relates to a composition for preventing or treating cellular senescence-associated diseases comprising salinomycin as an active ingredient, which acts differently depending on the type of senescent cells, and it was confirmed that salinomycin exhibits a senomorphics effect of restoring the function and morphology of fibroblasts and vascular endothelial cells in which senescence is induced and exhibits a senolytics effect of selectively killing aging-induced retinal pigmented epithelial cells, and exhibits a senomorphics effect of restoring the function and morphology of cells, and thus the salinomycin acts differently depending on the type of cells to effectively prevent or treat senile eye disease, tissue fibrosis disease, atherosclerosis, osteoarthritis, degenerative brain disease, chronic skin damage, obesity and diabetes caused by cellular aging and can be provided as a composition for life extension.
Owner:RES COOPERATION FOUND OF YEUNGNAM UNIV
Dna-fish method for measurement of telomere length
Provided are methods and compositions useful for assessing the length of telomeres. The disclosed methods and compositions are amenable to performance as a high-throughput method to assess telomere length (TL) and TL constitution using genomic DNA. Also provided are methods for diagnosing a telomere-related condition or disease in a subject, assessing general health and / or aging of a subject, establishing a relationship between telomere constitution and cancer and / or aging-related disease, assessing exposure to harmful substances and / or stresses of a subject, assessing response to a drug or drugs treatment of a subject, assessing disease risk of a subject, and assessing clinical outcome of a subject who is suffering from a disease / diseases. The methods are useful in studies of individuals and populations.
Owner:GEORGETOWN UNIV
A carotid artery aging prediction method based on elastic modulus
ActiveCN109171812BHigh reference valueOrgan movement/changes detectionInfrasonic diagnosticsAging-associated diseasesIntimal media thickness
The invention discloses a method for predicting carotid artery aging based on elastic modulus. The method includes establishing a carotid artery aging model. The model uses the elastic modulus and intima-media thickness of the carotid artery as evaluation marks. The nonlinear relationship between age and carotid elastic modulus and intima-media thickness can be used to describe the aging process of cardiovascular with age. The variation law of the carotid intima-media thickness and elastic modulus of each age group described in the present invention is basically consistent with the data detected in relevant medical literature, showing that it is effective to express the relationship between aging and intima-media thickness with the segmented method The elastic modulus of the carotid artery is an objective index for evaluating cardiovascular aging, so this model can be used to assist in the analysis of the occurrence and development of cardiovascular aging and related diseases, and provides new ideas for the prevention and treatment of various aging-related diseases , opened up new horizons.
Owner:NANJING UNIV OF POSTS & TELECOMM
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com